Mar 11, 2014 at 19:10 | Source: CNBC-TV18
Compulsory licence is a tool through which developing countries like India can produce patented drugs, can allow companies to produce patented drugs in a much cheaper and affordable way.
Mar 07, 2014 at 15:27 | Source: CNBC-TV18
Biocon CMD Kiran Mazumdar-Shaw said the companys research efforts are focused on a number of programs that deliver drugs that women can benefit from.
Mar 06, 2014 at 19:45 | Source: Reuters
An Indian committee is reviewing up to a dozen patented drugs to see if so-called compulsory licences, which in effect break exclusivity rights, can be issued for some of them, two senior government officials said last month.
Feb 28, 2014 at 09:29 | Source: Moneycontrol.com
The key drug which is to be studied for epilepsy is Levetiracetam ER. The estimated peak sales at USD 35-50 million and it may be approved by FY16.
Feb 24, 2014 at 13:11 | Source: Moneycontrol.com
Zydus Pharmaceutical USA, a subsidiary of Ahmedabad-based Cadila Healthcare, has received approval from US Food and Drug Administration for Clonidine Hydrochloride injection (with strength of 0.1 MG/ML and 0.5 MG/ML ) on February 20.
Feb 07, 2014 at 22:27 | Source: CNBC-TV18
The Delhi High Court (HC) has thrown a wrench into plans of Biocon and Mylan to market a breast cancer drug that goes by the scientific name Trastuzumab.
Feb 06, 2014 at 15:50 | Source: Reuters
An Indian government committee is reviewing patented drugs of foreign firms to see if so-called compulsory licences, which in effect break exclusivity rights, can be issued for some of them to bring down costs, two senior government officials told Reuters.
Feb 04, 2014 at 09:59 | Source: PTI
The company's subsidiary Mylan Pharmaceuticals Pvt Ltd has launched the world's first trastuzumab biosimilar, which will be marketed by Mylan under the brand name Hertraz Herceptin, a company statement said.
Feb 01, 2014 at 14:25 | Source: CNBC-TV18
Currently there is a trend that the so-called noval combinations are researched because if you use several approaches to tackle cancer, the cancer cells have less of a chance to evade.
Jan 24, 2014 at 08:47 | Source: Moneycontrol.com
Sun Pharma Advanced Research Company (SPARC) announced that its licensee has received an approval from the Drug Controller General of India (DCGI) for Paclitaxel Injection Concentrate for Nanodispersion (PICN), indicated for the treatment of metastatic breast cancer.